TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05590676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg.
Study: NCT05436418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
Study: NCT05590676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg.
Study: NCT04892303

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)
Description: To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
Study: NCT04914312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maqui berry/omeg-3 fatty acids
Description: 2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
Study: NCT05505786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wide stance width
Description: Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
Study: NCT06229093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma
Description: For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synchrony
Description: For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
Study: NCT06575400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3804379
Description: BI 3804379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3804379
Description: BI 3804379
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
Study: NCT06575400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3804379
Description: Placebo matching BI 3804379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3804379
Description: Placebo matching BI 3804379
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
Study: NCT05506345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative Drama Workshop
Description: * The host introduces the theme and stressor scene of this workshop~  * Nursing students group discussion~    * Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events
Study: NCT05692518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGNET System, DI Bio-fragmentable
Description: Anastomoses achieved by magnetic compression.
Study: NCT06226870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal tretment
Description: traditional therapy
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.
Study: NCT06226870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biodentin VPT
Description: Alternative therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Alternative therapy
Study: NCT05061862

Intervention type: DEVICE
Intervention: cardiac implantable electronic devices (CIEDs)
Description: Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure and/or non-invasive diagnostic collection at follow-up visits, as applicable.
Study: NCT04826250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of medication
Description: Either morning or nighttime medication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of medication
Description: Either morning or nighttime medication
Study: NCT06252662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: block duration extension additive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Control arm, comparison for block duration with dexmedetomidine
Study: NCT04728620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Care Gaps Patient Portal Intervention
Description: The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
Study: NCT06252623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide will be purchased commercially as Bydureon® for subcutaneous injection and administered at 2 mg once a week for 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline will be used as the placebo and administered subcutaneously once a week for 6 weeks.
Study: NCT05414929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Description: HPV self-sampling (Cobas Uniswab)
Study: NCT05029726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine
Description: Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline in 30cc syringes administered using ESPB technique
Study: NCT06090708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt with probiotic bacteria
Description: Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
Study: NCT05841693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will be offered same amount of placebo fluid.
Study: NCT06086353

Intervention type: DRUG
Intervention: Tafamidis
Description: Patients on tafamidis will be observed
Study: NCT05696327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tyler Twist Exercises
Description: Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
Study: NCT05308316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose cigarettes
Description: Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.
Study: NCT06000111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 Days of face-down positioning
Description: Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 Days of face-down positioning
Description: Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
Study: NCT06232590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (comfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (comfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (lehfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (lehfilcon A)
Description: Multifocal monthly replacement contact lens for 1 month
Study: NCT05543551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing with Resistance Training
Description: Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees.
Study: NCT06507553

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent-Darwin influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent-Darwin influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Augment-Tasmania influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Augment-Tasmania influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT05590234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 20 ml of bupivacaine 0.25%,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 20 ml of bupivacaine 0.25%,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20 ml of normal saline 0.9%.
Study: NCT06390982

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
Study: NCT06507553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV-2X Darwin influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV-2X Darwin influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent-Tasmania influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT05543551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic breathing with out resistance training
Description: Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed
Study: NCT05425355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) acetaminophen + oral placebo
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) placebo plus oral acetaminophen
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
Study: NCT06507553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent-Tasmania influenza vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT05442190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
Study: NCT05471557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery
Description: Experimental pain paradigm delivered that is short-term and painful but not harmful.
Study: NCT05866237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Engagement tool
Description: The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 and Flu vaccinations through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
Study: NCT05578872

Intervention type: DRUG
Group type: OTHER
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab administered by intravenous (IV) infusion
Study: NCT05649137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study: NCT06390982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
Study: NCT05649137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.